Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 359-362

  Briand, François ^a   Prunet Marcassus, Bénédicte ^a   Thieblemont, Quentin ^a   Costard, Clément ^a   Muzotte, Elodie ^a   Sordello, Sylvie ^a   Sulpice, Thierry ^a  

^a Physiogenex SAS   (France)

Author keywords

Cholesteryl ester transfer protein inhibition; Glucose metabolism; High density lipoprotein; Insulin resistance; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; GLUCOSE; GLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TORCETRAPIB; TRIACYLGLYCEROL; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; DEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LABELING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLYCEROL BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; SOLEUS MUSCLE; SYRIAN HAMSTER; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROGENIC DIET; BLOOD; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; DYSLIPIDEMIAS; ENZYME ACTIVATION; FECES; HAMSTER; HOMEOSTASIS; HYPERGLYCEMIA; MESOCRICETUS; METABOLISM; RANDOMIZATION; SKELETAL MUSCLE; SPECIES DIFFERENCE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CRICETINAE; DEOXYGLUCOSE; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; ENZYME ACTIVATION; FECES; GLUCOSE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MESOCRICETUS; MUSCLE, SKELETAL; QUINOLINES; RANDOM ALLOCATION; SPECIES SPECIFICITY;

EID: 84896288376     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.028     Document Type: Article

References (16)

1. Miller G.J., Miller N.E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975, 1:16-19.
2. Bochem A.E., Kuivenhoven J.A., Stroes E.S. The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. Curr Pharm Des 2013, 19:3143-3149.
3. Briand F. The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport. Curr Opin Investig Drugs 2010, 11:289-297.
4. Drew B.G., Rye K.A., Duffy S.J., Barter P., Kingwell B.A. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8:237-245.
5. Drew B.G., Duffy S.J., Formosa M.F., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111.
6. Barter P.J., Rye K.A., Tardif J.C., et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Circulation. 2011, 124:555-562.
7. Briand F., Thieblemont Q., Muzotte E., Sulpice T. Up regulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol 2013, 33:13-23.
8. Castro-Perez J., Briand F., Gagen K., et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. JLipid Res 2011, 52:1965-1973.
9. Duehlmeier R., Sammet K., Widdel A., et al. Distribution patterns of the glucose transporters GLUT4 and GLUT1 in skeletal muscles of rats (Rattus norvegicus), pigs (Sus scrofa), cows (Bos taurus), adult goats, goat kids (Capra hircus), and camels (Camelus dromedarius). Comp Biochem Physiol A Mol Integr Physiol 2007, 146:274-282.
10. Zhang Q., Zhang Y., Feng H., et al. High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS One 2011, 6:e23556.
11. Drew B.G., Carey A.L., Natoli A.K., et al. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. JLipid Res 2011, 52:572-581.
12. Karavia E.A., Papachristou D.J., Liopeta K., Triantaphyllidou I.E., Dimitrakopoulos O., Kypreos K.E. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. Mol Med 2012, 18:901-912.
13. Gordts S.C., Singh N., Muthuramu I., De Geest B. Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions. Curr Mol Med 2013, [in press].
14. Moore M.C., Coate K.C., Winnick J.J., An Z., Cherrington A.D. Regulation of hepatic glucose uptake and storage invivo. Adv Nutr 2012, 3:286-294.
15. Russell R.R., Bergeron R., Shulman G.I., Young L.H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Phys 1999, 277:H643-H649.
16. Siebel A.L., Natoli A.K., Yap F.Y., et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 2013, 113:167-175.